Journal: Respiratory Research

Article Title: Gene profile of fibroblasts identify relation of CCL8 with idiopathic pulmonary fibrosis

doi: 10.1186/s12931-016-0493-6

Figure Lengend Snippet: Genes showing 10-fold or greater changes in gene expression between the IPF and control groups

Article Snippet: In addition, we measured the CCL8 protein amount in supernatants and cell lysates of the cultured fibroblasts (1 × 10 6 ) using CCL8 ELISA kit (Abnova, Taipei, Taiwan).

Techniques: Gene Expression, Control

Journal: Respiratory Research

Article Title: Gene profile of fibroblasts identify relation of CCL8 with idiopathic pulmonary fibrosis

doi: 10.1186/s12931-016-0493-6

Figure Lengend Snippet: CCL8 mRNA and protein levels in lung tissue-derived fibroblasts from 14 IPF patients and 10 controls. ( a ) RT-PCR, ( b ) densitometry of the CCL8 RT-PCR band intensity normalized to that of β-actin, ( c ) real-time PCR, and ( d ) correlations of the CCL8 mRNA levels of 12 subjects determined by the transcriptome chip with those by real-time PCR. e , f CCL8 protein level of Culture media and cell lysate, and ( g ) correlations of the CCL8 protein levels and CCL8 mRNA levels of 24 subjects determined by the ELISA with those by real-time PCR. The data were presented as median values with 25 and 75% quartiles

Article Snippet: In addition, we measured the CCL8 protein amount in supernatants and cell lysates of the cultured fibroblasts (1 × 10 6 ) using CCL8 ELISA kit (Abnova, Taipei, Taiwan).

Techniques: Derivative Assay, Reverse Transcription Polymerase Chain Reaction, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay

Journal: Respiratory Research

Article Title: Gene profile of fibroblasts identify relation of CCL8 with idiopathic pulmonary fibrosis

doi: 10.1186/s12931-016-0493-6

Figure Lengend Snippet: CCL8 protein concentrations in BAL fluids and ROC curves. a CCL8 protein was detected in 25 of 41 normal controls, 80 of 86 IPF patients, 11 of 22 NSIP patients, 8 of 20 HP patients and 13 of 19 sarcoidosis patients. Open and closed circles indicate CCL8 protein levels detected (>1.5pg/mL) and those below the lower limit of detection, respectively. The data were presented as median values with 25 and 75% quartiles. b ROC curve of the CCL8 protein concentration between the two groups. A cut-off value of 2.17pg/mL had 80.2% accuracy, 86.0% specificity, and 65.7% sensitivity for differentiating IPF patients from controls. c ROC curve of the CCL8 protein concentration between the other interstitial lung diseases groups. A cut-off value 0.53pg/mL had 70.7% accuracy, 91.9% specificity, 57.4% sensitivity between the IPF patients and the other interstitial lung diseases group. d A Kaplan-Meier plot of 69 subjects with IPF followed up for 1to 8 years. The percent survival rate was markedly lower in the group with a CCL8 level of >28.61 pg/mL (red line) compared with that in the group with a CCL8 level of <28.61 pg/mL (black line) (hazard ratio = 3.93, CI: 1.25–12.39, p = 0.012)

Article Snippet: In addition, we measured the CCL8 protein amount in supernatants and cell lysates of the cultured fibroblasts (1 × 10 6 ) using CCL8 ELISA kit (Abnova, Taipei, Taiwan).

Techniques: Protein Concentration

Journal: Respiratory Research

Article Title: Gene profile of fibroblasts identify relation of CCL8 with idiopathic pulmonary fibrosis

doi: 10.1186/s12931-016-0493-6

Figure Lengend Snippet: Representative double immunofluorescence-stained images of IPF and control lung tissues. CCL8 and α-smooth muscle actin (α-SMA) were stained using PE- (red) and FITC-conjugated antibodies (green), respectively. A proportion of interstitial fibroblasts (IT) and the peribronchial and vascular area (VS) showed staining for both CCL8 and α-SMA (magnification, 200×)

Article Snippet: In addition, we measured the CCL8 protein amount in supernatants and cell lysates of the cultured fibroblasts (1 × 10 6 ) using CCL8 ELISA kit (Abnova, Taipei, Taiwan).

Techniques: Immunofluorescence, Staining, Control

Journal:

Article Title: CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease

doi: 10.1182/blood-2007-06-097287

Figure Lengend Snippet: CCL8 expression in human serum after HSCT. Serum was obtained at several time points after HSCT. The results of immunoSELDI using antibody specific for human CCL8 are shown. Box highlights peak of human CCL8. The predicted molecular mass of mature human CCL8 is 8920 Da. (A) Patient A developed clinical GVHD on day 13 after HSCT and methyl prednisolone (mPSL) was administered the same day. The peak profile of CCL8 was very weak on day 0 with an obvious increase on day 10. CCL8 then declined on day 21 after mPSL treatment, but was again up-regulated on day 33. The peak intensity of 8920 Da was 9.6, 40.6, 19.5, and 52.5 on days 0, 10, 21, and 33, respectively. (B) In patient B, no CCL8 peak was detected on day 0, but was increased on days 9 and 19, and decreased on days 21 and 30. Clinical GVHD was overt on day 19 and mPSL treatment was started. The peak intensity of 8920 Da is 2.1, 14.3, 41.4, 12.3, and 12.7 on days 0, 9, 19, 21, and 30, respectively. (C) No GVHD developed in patient C throughout the course. CCL8 peak was very low in all samples examined. The peak intensity of 8920 Da is 5.8, 12.8, 4.1, 6.5, 6.2, and 3.0 on days −7, −1, 10, 20, 34, and 38, respectively. (D) An example of CCL8 expression in a healthy control is shown. CCL8 peak is very low. The peak intensity of 8920 Da is 5.3.

Article Snippet: The human CCL8 ELISA kit was purchased from RayBiotech (Norcross, GA) and the mouse IL-6 kit from R&D Systems (Minneapolis, MN).

Techniques: Expressing

Journal:

Article Title: CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease

doi: 10.1182/blood-2007-06-097287

Figure Lengend Snippet: Protein identification using mass spectrometry. (A) A representative MS spectrum (682.3332 m/z) of the peptide from the candidate spot in Figure 4C is shown, which was identified by nanoLC-MS/MS. (B) The deduced sequence is confirmed by MS/MS spectra of b and y ion series as CCL8 peptide (QGMSLCVDPTQK) corresponding to 682.3332 parent ion in panel A. Cysteine is carbamidomethylated in this peptide. (C) Verification of CCL8 as the 8972-Da peak by immunoSELDI is shown. The box highlights the elevation of CCL8 in the GVHD sample but not in the control sample.

Article Snippet: The human CCL8 ELISA kit was purchased from RayBiotech (Norcross, GA) and the mouse IL-6 kit from R&D Systems (Minneapolis, MN).

Techniques: Mass Spectrometry, Tandem Mass Spectroscopy, Sequencing

Journal:

Article Title: CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease

doi: 10.1182/blood-2007-06-097287

Figure Lengend Snippet: Concentration of CCL8 in human sera. Concentration of CCL8 in human sera was determined by ELISA for human CCL8. All sera from those who did not develop GVHD after HSCT (non-GVHD/HSCT) contained less than 48 pg/mL (mean ± SE: 22.5 ± 5.5 pg/mL, range: 12.6-48.0 pg/mL, n = 7). CCL8 was highly up-regulated in GVHD plasma (GVHD/HSCT) ranging from 52.0 to 333.6 pg/mL (mean ± SE: 165.0 ± 39.8 pg/mL, n = 7). Two patients with severe, eventually fatal, GVHD showed extremely high levels of CCL8 (ie, 333.6 and 290.4 pg/mL). In healthy controls (donors), mean concentration of CCL8 was 18.9 pg/mL (range: 0.00 to 32.6 pg/mL, n = 8). The difference in serum concentration of CCL8 was statistically significant between non-GVHD and GVHD plasma obtained from patients undergoing HSCT.

Article Snippet: The human CCL8 ELISA kit was purchased from RayBiotech (Norcross, GA) and the mouse IL-6 kit from R&D Systems (Minneapolis, MN).

Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay

Journal: Journal of Translational Medicine

Article Title: Fasting mimicking diet inhibits tumor-associated macrophage survival and pro-tumor function in hypoxia: implications for combination therapy with anti-angiogenic agent

doi: 10.1186/s12967-023-04577-7

Figure Lengend Snippet: Bioinformatics analysis of the correlation between CCL8 and FMD. A Differential gene expression (GEO database, dataset GSE50712, Control vs. EVE-treated breast tumor bearing mice) is determined using GEO2R; the log-fold-change is used to rank the genes. B – D The expression of CCL8, TGFB1, and HGF in invasive breast cancer samples from the TCGA database. E KEGG enrichment analysis for data from the GEO database (dataset GSE37956, control vs. bevacizumab treated glioblastoma xenograft tumor). F The expression of CCL8, TGFB1, PKG1, LDHA, and HIF1A in GEO database (dataset GSE37956, control vs. bevacizumab treated glioblastoma xenograft tumor). G , H Correlation between CCL8, TGFBI and immune cell infiltration in invasive breast cancer samples from the TCGA database. I GSVA analysis of correlation between CCL8, hypoxia (Gene set from GESA M34030), glycolysis (Gene set from GESA M5113), glucose starvation (Gene set from GESA M15497), mTOR (Gene set from GESA M2672), macrophage (Gene set from GESA M39708), M2 macrophage (Gene set from GESA M8527), M1 macrophage (Gene set from GESA M6586) in invasive breast cancer samples from the TCGA database

Article Snippet: Lactate acid assay kit (NJJCBIO, Wuhan, China); glucose assay kit (NJJCBIO, Wuhan, China); cell counting kit-8 assay (Meilun, Dalian, China); human and mouse CCL8 mini ABTS ELISA development kit (PeproTech, Hamburg, Germany).

Techniques: Expressing

Journal: Journal of Translational Medicine

Article Title: Fasting mimicking diet inhibits tumor-associated macrophage survival and pro-tumor function in hypoxia: implications for combination therapy with anti-angiogenic agent

doi: 10.1186/s12967-023-04577-7

Figure Lengend Snippet: FMD inhibits the secretion of CCL8 by TAMs. A Serum CCL8 level in mice is detected by ELISA (* P < 0.05, vs. respective control group, # P < 0.05, vs. respective TAM group). B CCL8 secretion from TAMs treated for 24 h with GD or EVE (100 nM) or 2-DG (10 mM), or 2ME2 (10 µM) is determined by ELISA (* P < 0.05, vs. respective TAM group). C CCL8 mRNA levels in TAMs are determined by RT-PCR (* P < 0.05, vs. respective TAM group). D Migration of MDA-MB-231 cells, after co-incubation with TAMs and low (L) or high doses (H) of CCL8 antibody, is determined in a transwell assay (magnification, ×40)

Article Snippet: Lactate acid assay kit (NJJCBIO, Wuhan, China); glucose assay kit (NJJCBIO, Wuhan, China); cell counting kit-8 assay (Meilun, Dalian, China); human and mouse CCL8 mini ABTS ELISA development kit (PeproTech, Hamburg, Germany).

Techniques: Enzyme-linked Immunosorbent Assay, Reverse Transcription Polymerase Chain Reaction, Migration, Incubation, Transwell Assay

Journal: Animals : an Open Access Journal from MDPI

Article Title: Inflammatory Markers in Uterine Lavage Fluids of Pregnant, Non-Pregnant, and Intrauterine Device Implanted Mares on Days 10 and 15 Post Ovulation

doi: 10.3390/ani11123493

Figure Lengend Snippet: RIA/ELISA kit names for analyses. CVs: intra and inter-assay coefficients of variation; E 2 : estradiol-17α; NO: nitric oxide; PG: prostaglandin; IL: interleukin.

Article Snippet: IL-8 (pg/mL) , Horse C-C Motif Chemokine 8/MCP2 (CCL8) ELISA Kit, Equine , Abbexa; abx575576 , 15.6–1000 , 10.0%/12.0%.

Techniques: Inter Assay, Enzyme-linked Immunosorbent Assay